Enlivex Therapeutics Announces Presentation of Promising Allocetra™ Clinical Trial Data in Knee Osteoarthritis at EULAR 2025

Reuters

2025/06/10

Enlivex <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Presentation of Promising Allocetra™ Clinical Trial Data in Knee Osteoarthritis at EULAR 2025

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has announced that it will present clinical data from its ongoing study of Allocetra™, a macrophage reprogramming cell therapy, at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology. The conference is scheduled to take place from June 11-14, 2025, in Barcelona, Spain. The presentation will feature data from a Phase I/II trial evaluating Allocetra™ in patients with knee osteoarthritis. The therapy has shown promising results in terms of safety and efficacy, including pain reduction and improved joint function. The company has completed patient enrollment for the Phase II stage of the trial and anticipates releasing topline data by August 2025. Enlivex representatives, including CEO Dr. Oren Hershkovitz and CMO Dr. Einat Galamidi, will attend the conference to engage with stakeholders and the scientific community.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9465860-en) on June 10, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2542331490"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542331490\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2542331490?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-10 20:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542331490","market":"us","top_or_hot":-1,"title":"Enlivex Therapeutics Announces Presentation of Promising Allocetra™ Clinical Trial Data in Knee Osteoarthritis at EULAR 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Enlivex <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Presentation of Promising Allocetra™ Clinical Trial Data in Knee Osteoarthritis at EULAR 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ENLV\">Enlivex Therapeutics Ltd.</a> (Nasdaq: ENLV) has announced that it will present clinical data from its ongoing study of Allocetra™, a macrophage reprogramming cell therapy, at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology. The conference is scheduled to take place from June 11-14, 2025, in Barcelona, Spain. The presentation will feature data from a Phase I/II trial evaluating Allocetra™ in patients with knee osteoarthritis. The therapy has shown promising results in terms of safety and efficacy, including pain reduction and improved joint function. The company has completed patient enrollment for the Phase II stage of the trial and anticipates releasing topline data by August 2025. Enlivex representatives, including CEO Dr. Oren Hershkovitz and CMO Dr. Einat Galamidi, will attend the conference to engage with stakeholders and the scientific community.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9465860-en) on June 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Enlivex Therapeutics Announces Presentation of Promising Allocetra™ Clinical Trial Data in Knee Osteoarthritis at EULAR 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnlivex Therapeutics Announces Presentation of Promising Allocetra™ Clinical Trial Data in Knee Osteoarthritis at EULAR 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-10 20:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Enlivex <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Presentation of Promising Allocetra™ Clinical Trial Data in Knee Osteoarthritis at EULAR 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ENLV\">Enlivex Therapeutics Ltd.</a> (Nasdaq: ENLV) has announced that it will present clinical data from its ongoing study of Allocetra™, a macrophage reprogramming cell therapy, at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology. The conference is scheduled to take place from June 11-14, 2025, in Barcelona, Spain. The presentation will feature data from a Phase I/II trial evaluating Allocetra™ in patients with knee osteoarthritis. The therapy has shown promising results in terms of safety and efficacy, including pain reduction and improved joint function. The company has completed patient enrollment for the Phase II stage of the trial and anticipates releasing topline data by August 2025. Enlivex representatives, including CEO Dr. Oren Hershkovitz and CMO Dr. Einat Galamidi, will attend the conference to engage with stakeholders and the scientific community.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9465860-en) on June 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4112","symbol_name":"金融交易所和數據","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nNDL4N1hkK:1","article_id":"2542331490","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542331490","pubTimestamp":1749558772,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Enlivex Therapeutics Ltd.  has announced that it will present clinical data from its ongoing study of Allocetra, a macrophage reprogramming cell therapy, at the European Alliance of Associations for Rheumatology  European Congress of Rheumatology. The conference is scheduled to take place from June 11-14, 2025, in Barcelona, Spain. The presentation will feature data from a Phase I/II trial evaluating Allocetra in patients with knee osteoarthritis. The therapy has shown promising results in terms of safety and efficacy, including pain reduction and improved joint function. The company has completed patient enrollment for the Phase II stage of the trial and anticipates releasing topline data by August 2025. Enlivex representatives, including CEO Dr. Oren Hershkovitz and CMO Dr. Einat Galamidi, will attend the conference to engage with stakeholders and the scientific community.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While P","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4112":"金融交易所和数据","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4139":"生物科技","BK4585":"ETF&股票定投概念","ENLV":"Enlivex Therapeutics Ltd.","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","NDAQ":"纳斯达克OMX交易所"},"translate_title":"Enlivex Therapeutics宣布在EULAR 2025上展示有希望的Allocetra™膝骨关节炎临床试验数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ENLV":0.9},"content_text":"Enlivex Therapeutics Announces Presentation of Promising Allocetra™ Clinical Trial Data in Knee Osteoarthritis at EULAR 2025\n    \n\nEnlivex Therapeutics Ltd. (Nasdaq: ENLV) has announced that it will present clinical data from its ongoing study of Allocetra™, a macrophage reprogramming cell therapy, at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology. The conference is scheduled to take place from June 11-14, 2025, in Barcelona, Spain. The presentation will feature data from a Phase I/II trial evaluating Allocetra™ in patients with knee osteoarthritis. The therapy has shown promising results in terms of safety and efficacy, including pain reduction and improved joint function. The company has completed patient enrollment for the Phase II stage of the trial and anticipates releasing topline data by August 2025. Enlivex representatives, including CEO Dr. Oren Hershkovitz and CMO Dr. Einat Galamidi, will attend the conference to engage with stakeholders and the scientific community.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9465860-en) on June 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}